AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KAUG 66 min read$KVUE

Kenvue Inc. (KVUE): Results of Operations and Financial Condition

Kenvue Inc. (KVUE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q226earningspressrelease.htm EX-99.1 Document Kenvue Reports Second Quarter 2026 Results • Delivered Third Consecutive Quarter of Net and Organic Sales 1 Growth • Net Sales Increased 3.0%; Organic Sales Increased 1.6% • Diluted EPS Increased 9% to $0.24; Adjusted Dilute

Original reporting
SEC EDGAR 8-K
Published Aug 6, 2026, 10:48 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 11:05 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$KVUE
Neutral
medium confidence
Mentioned
$KVUE
Relevance
8/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$KVUENeutralMed
01

Why it matters

The earnings release provides updated operating performance (sales, EPS, margins) but removes forward-looking guidance due to the pending transaction, increasing reliance on deal-related updates for future expectations.

02

Market read

Traders get a fresh datapoint on Q2 performance plus an explicit guidance blackout tied to the Kimberly-Clark combination, which can shift near-term positioning.

03

What to watch

Gross and operating margins declined year over year, with inflation, tariffs, and FX cited as drivers, which could cap upside despite sales growth.

Relevance 8/10Novelty 8/10Timing: filed pre-market today, Q2 results and guidance blackout disclosed

Background

Kenvue filed an SEC 8-K for Q2 2026 results (fiscal quarter ended June 28, 2026) and referenced its planned value-creating combination with Kimberly-Clark expected in Q4 2026.

Company-level read

Ticker impact

$KVUENeutralMedium confidence
Context

Kenvue reported Q2 results with net sales up 3.0% and EPS up, while also stating it will not provide forward guidance due to the Kimberly-Clark combination.

Expected impact

Near-term volatility risk is elevated around deal-related headlines, while the earnings print itself is likely supportive but not decisive without guidance.

Evidence & confidence

The filing provides concrete Q2 financial metrics and explicitly removes forward-looking guidance, which can shift expectations and increase sensitivity to transaction progress.

Market effects

Sector

Consumer staples and OTC/pharma-adjacent peers may see read-through on demand resilience and margin sensitivity to inflation/tariffs.

Regional

Performance commentary highlights strength in North America, EMEA, and Asia Pacific, which can influence regional consumer staples sentiment.

Global

Foreign currency benefit and tariff/inflation impacts underscore macro sensitivity for multinational consumer brands.

Counterpoint

What could challenge this read

The guidance blackout reduces the usefulness of the earnings beat, so the market may discount the print and focus on deal execution risk instead.

Key entities

  • public_company
    Kenvue Inc.

    Reported Q2 2026 net sales, EPS, margin metrics, and stated it will not provide forward-looking guidance due to the Kimberly-Clark transaction.

  • public_company
    Kimberly-Clark

    Counterparty in Kenvue’s pending combination referenced as expected in Q4 2026.

  • person
    Kirk Perry

    Kenvue CEO quoted on sales growth, operational efficiencies, and transformation progress.

Read at source← All news

Related articles

AUG 7
$KMBMed

Kimberly-Clark to Consolidate Operations, Invest in Digital Optimizations Ahead of Kenvue Acquisition

Kimberly-Clark said it will consolidate 6,000 applications and more than 15 ERP systems as it nears completion of its Kenvue acquisition. On an earnings call, COO Russell Torres cited a three-year plan targeting $1.9 million in savings and identified over $600 million of savings, with system integration and supply chain and commercial integration as key drivers.

consumergoods.com4 min
AUG 6
$APPMed

Dow slips, Nasdaq moves level as earnings keep markets on edge

U.S. stocks opened mixed as investors digested earnings and economic data. AppLovin (APP) fell over 20% after Q2 revenue of $1.924B missed estimates. Datadog (DDOG) dropped over 18% on weaker bookings and guidance. SpaceX (SPCX) rose about 2.5% after a lockup expiry. Western Digital (WDC) slid 11% on margin outlook; Fiserv (FI) and Kenvue (KVUE) also fell.

proactiveinvestors.com7 min
AUG 6
$KVUEMed

Kenvue second quarter results fall short of expectations, sending shares lower

Kenvue (NYSE:KVUE) shares fell about 2% after its Q2 results narrowly missed Wall Street expectations. Adjusted diluted EPS was $0.31 vs $0.32 expected, and revenue was $3.96B vs $3.97B. Net sales rose 3%, but margins declined, with gross margin at 58.2% vs 58.9% a year earlier. Kenvue cited inflation, tariffs and FX and gave no forward guidance due to a planned Kimberly-Clark combination.

proactiveinvestors.com3 min
AUG 6
$KVUEMed

Kenvue misses quarterly estimates as inflation, tariffs squeeze margins

Kenvue reported Q2 adjusted profit of 31 cents per share, slightly below analysts’ 32 cents estimate, and sales rose 3% to $3.96 billion, just under the $3.97 billion forecast, according to LSEG. Adjusted gross margin fell to 60.2% from 60.9% as inflation, tariffs and currency costs pressured margins. Kenvue expects $250 million in 2026 pre-tax restructuring charges and says a $40 billion Kimberly-Clark buyout should close in Q4 2026.

yahoo.com3 min
JUL 31
$KVUEMedAI 8/10

FDA approves long-lasting OTC pain reliever combining acetaminophen and naproxen

The FDA approved an OTC pain reliever combining acetaminophen and naproxen sodium, marketed by Kenvue as Tylenol with Naproxen. Kenvue says it starts working within 30 minutes and lasts up to 12 hours, and cites eight studies showing better relief than either ingredient alone. The FDA allows use for temporary relief of minor aches and pains in adults and children 12+.

kztv10.com3 min
JUL 30
$PGMed

Drugmakers, retailers must face ’maximum strength’ claim in decongestant false ad litigation in US

Nasdaq sees best day in over a month as Microsoft breathes life back into AI trade By Jonathan Stempel NEW YORK, July 30 (Reuters) - A federal appeals court on Thursday revived portions of nationwide litigation in which consumers accused drugmakers such as Procter & Gamble and retailers such as CVS of selling billions of dollars of over-the-counter decongestants that didn’t work. The litigation comprised about 100 lawsuits filed after a U.S.

investing.com4 min